Liposomal Bupivacaine Versus Standard of Care in Total Knee Surgery

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether liposomal bupivacaine is effective in the management of pain following total knee arthroplasty, as compared to standard of care analgesia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OhioHealth
• Treatments: Bupivacaine; Ketorolac; Ketorolac Tromethamine; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Morphine; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Ropivacaine

Criteria

Inclusion Criteria:

• At least 18 years of age

• Scheduled to undergo total knee arthroplasty (TKA) performed by the principal investigator

Exclusion Criteria:

• Age <18 years

• Pregnant or breastfeeding

• Non-English-speaking

• Unable to give informed consent

• Patients admitted from or discharged to a medical facility (due to likelihood of limited mobility and/or required minimum lengths of stay, confounding primary outcome), including other hospitals, skilled nursing facilities, long-term acute care hospitals, etc.

• Patients unable to complete a device-assisted 140 foot walk at baseline

• Patients with contraindication(s) to any bupivacaine or ropivacaine formulation, to nerve blocks or any of the local agents used (IV morphine, ketorolac, or methylprednisolone).

• Patients on a long-acting maintenance opioid prior to admission for surgery (e.g., methadone, oxycontin)

• Patients undergoing simultaneous bilateral TKAs, as this would increase the dose of Exparel per patient (we are limited to one dose per patient)